TB-500 Fragment 17-23: The Short Actin-Binding Peptide Explained

TB-500 fragment 17-23 is a seven-amino-acid synthetic peptide, LKKTETQ, that copies positions 17 through 23 of the thymosin beta-4 protein. Researchers study it as the smallest piece of thymosin beta-4 that still binds actin, while full-length TB-500 is the complete 43-amino-acid molecule. Neither TB-500 nor TB-500 fragment 17-23 is FDA-approved for human use in the United States, and both are sold as research chemicals only.

The fragment also appears in the literature and on supplier labels as TB-500 frag 17-23, TB4 fragment 17-23, or simply the actin-binding fragment. It is not a drug, a supplement, or a finished therapeutic product.

What Is TB-500 Fragment 17-23?

Thymosin beta-4 is a naturally occurring protein found in most human cells, and its best-known job is sequestering actin, the building block of the cell's internal skeleton. TB-500 is the synthetic, full-length version of that protein. TB-500 fragment 17-23 trims the molecule down to the short stretch that performs the actin binding.

Key facts about the fragment:

• Sequence: LKKTETQ (leucine, lysine, lysine, threonine, glutamate, threonine, glutamine)
• Approximate molecular weight: roughly 850 to 890 Da, depending on whether the peptide is acetylated
• Parent protein: thymosin beta-4, residues 17 through 23
• Typical form: lyophilized white powder for laboratory use
• Regulatory status: research chemical; not an approved drug anywhere

Scientists call residues 17-23 the active domain because the actin-binding motif lives there. That does not mean the rest of the protein is irrelevant. Other regions of thymosin beta-4 are associated with cell migration, anti-inflammatory signaling, and angiogenesis, so the fragment is narrower in scope than the full molecule.

TB-500 Fragment 17-23 vs TB-500: How They Differ

The most common question researchers ask is how the short fragment compares with the full-length peptide. The table below breaks down the practical differences.

Full-length product is widely sold as tb-500 thymosin beta-4 10mg lyophilized vials, while fragment 17-23 vials are smaller and less common. The fragment is cheaper per milligram and easier to characterize analytically, but it lacks the additional domains that full-length TB-500 contains.

Why Residues 17-23 Are Called the Actin-Binding Domain

Actin monomers link together to form filaments that let cells move, divide, and close wounds. Thymosin beta-4 keeps a pool of actin monomers in reserve by binding them, and the LKKTETQ sequence is the part that does the grabbing.

In cell-free experiments, the isolated heptapeptide binds actin monomers and inhibits polymerization in much the same way as the parent protein. That makes it a convenient tool compound for labs that want to study actin dynamics without working with a large, expensive protein.

A short 7-amino-acid fragment can reproduce the actin-binding behavior of thymosin beta-4 in test-tube assays, but it does not automatically reproduce every biological activity of the full-length protein. This is the central difference between tb 500 fragment 17 23 vs tb4 in a research setting.

What Preclinical Research Suggests

Almost all available data on this peptide family comes from cell cultures and animal models, not from controlled human trials. Studies on thymosin beta-4 and TB-500 have explored skin wound healing, corneal repair, cardiac tissue after injury, and tendon models in rodents.

Research on the 17-23 fragment is narrower. Most published work uses it as a biochemical probe for actin binding rather than as a therapy candidate. Important limitations to keep in mind:

• Small sample sizes and short follow-up periods in animal work
• Species differences that limit translation to humans
• Few independent replications of headline findings
• Almost no direct human data for either the fragment or full-length TB-500

Thymosin beta-4 is not a proven cure for any condition, and no human trial has established that TB-500 fragment 17-23 treats disease. People new to this category often begin by asking what is bpc-157 and tb-500, because the two peptides are discussed together so often in repair-focused research.

TB-500 Fragment 17-23 Dosage and Handling in Research

There is no established human dosage for TB-500 fragment 17-23, and no regulatory agency has reviewed it for human use. Most figures circulating online under a heading like tb 500 fragment 17 23 dosage are extrapolated from animal studies or borrowed from full-length TB-500 protocols, not derived from clinical data.

In laboratory work, the fragment is usually dissolved in buffer or water and used at micromolar concentrations in actin-polymerization assays. Animal studies of full-length TB-500 have used a wide range of injected doses over days to weeks. Those numbers cannot be converted into a safe or effective human dose.

Standard handling practices for lyophilized research peptides include:

1. Store the powder frozen, dry, and protected from light.
2. Reconstitute with bacteriostatic water or an appropriate buffer, swirling gently rather than shaking.
3. Refrigerate the reconstituted solution and use it within the timeframe the supplier specifies.
4. Follow sterile technique, because contaminated peptides are a genuine infection risk.

Anyone comparing protocols across compounds should know that questions about bpc-157 and tb-500 dosage for injury are just as unresolved, since neither peptide has an FDA-approved human dose.

Safety, Side Effects, and Legal Status

Reported tb-500 side effects from anecdotal human use include injection-site irritation, temporary fatigue, and headache, but these reports are unverified and come from uncontrolled settings. The larger issue is what remains unknown: no long-term human safety data, no studies in pregnant or breastfeeding people, and no standardized purity or sterility requirements for research-grade vials.

TB-500 is on the World Anti-Doping Agency's prohibited list, and the 17-23 fragment falls under the same class of banned substances for tested athletes. In the United States, these peptides are not approved for human use, and marketing them as treatments is illegal.

Purity is the practical concern for anyone browsing where to buy bpc-157 and tb-500. Reputable suppliers publish a third-party certificate of analysis with HPLC and mass spectrometry data, and a supplier that will not share one should be avoided. Anyone considering personal use of an unapproved peptide should discuss it with a licensed healthcare professional first.